Method for improving detection efficiency of in-situ proximity ligation technology

By introducing the combination of a clamp probe and a ring-forming probe to form a stable V-shaped structure, the problem of low detection efficiency of protein interaction in existing technologies is solved, realizing efficient and sensitive detection of protein interaction, which is suitable for cell and tissue research.

CN118995884APending Publication Date: 2024-11-22HUAQIAO UNIVERSITY
View PDF 0 Cites 5 Cited by

Patent Information

Application Number
CN202411247675.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing in-situ proximity linkage techniques still need improvement in terms of efficiency and sensitivity in detecting protein interactions, making it difficult to meet the growing needs of biomedical research.

Method used

A stable V-shaped structure is formed by combining a clamp probe and a ringing probe to mediate the ringing process. Combined with rolling circle amplification technology, the ringing efficiency and detection sensitivity are improved.

Benefits of technology

It significantly improves the detection efficiency and sensitivity of protein interactions, enabling quantitative and localized detection of protein interactions in cells and tissues, and providing a higher signal-to-noise ratio and signal amplification.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995884A_ABST
    Figure CN118995884A_ABST
Patent Text Reader

Abstract

The invention discloses a method for improving the detection efficiency of an in-situ proximity ligation assay. The method comprises the following steps: (1) treating a to-be-detected sample by using a first primary antibody and a second primary antibody; (2) respectively coupling the first secondary antibody and the second secondary antibody with the first oligonucleotide and the second oligonucleotide to construct a first conjugate and a second conjugate; (3) treating a sample to be detected by using the first conjugate and the second conjugate; (4) firstly adding a splint probe for treatment, then adding a ring forming probe for treatment to obtain a ring-shaped template, and then carrying out rolling circle amplification based on the ring-shaped template to obtain a rolling circle amplification product; and then adding a detection probe for treatment so as to identify a rolling circle amplification product, and further detecting through detection equipment so as to determine the interaction condition of the first protein and the second protein. According to the invention, quantitative and positioning detection of protein interaction in cells and tissues is realized, and sensitivity and efficiency of protein interaction detection are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of in situ proteomics, and in particular relates to a method for improving the detection efficiency of in situ proximity ligation technology. Background Art

[0002] The spatial expression of proteins is crucial for accurately identifying the localization and function of proteins in tissues and is closely related to the function of proteins in health and disease. Therefore, capturing the spatial and in situ proteome - that is, the localization of proteins at the subcellular level and their dynamic changes - is of great significance for a comprehensive understanding of cell biology. In situ proteomics is a technology that studies the distribution, localization, interaction and function of proteins in cells or tissues. It is an important branch of proteomics and provides higher spatial resolution and more accurate quantitative capabilities than traditional proteomics techniques.

[0003] In situ protein imaging based on antibody-oligonucleotide conjugates provides critical spatial localization information for a large number of cell types and protein interactions in mammals. Monitoring protein interactions in cells and tissues can reveal complex reactions between cellular and molecular structures. Protein interactions play a central role in a variety of cellular processes, including post-translational modifications (such as phosphorylation), signal transduction, neural development, and cancer. Currently, a variety of methods have been shown to be effective in detecting protein interactions. For example, traditional in situ proximity ligation technology has become a common method for identifying interacting proteins in cells and tissues. This technology mainly uses a pair of antibody-oligonucleotide conjugates and rolling circle amplification to visualize target protein interactions.

[0004] The UnFold probe is an improved design based on the existing in situ proximity ligation probe, which combines the conditions required to generate a circular amplification template, thereby improving the detection efficiency. Similarly, the proximity-dependent initiation of the hybridization chain reaction is also based on the dual-target recognition of the secondary antibody-oligonucleotide conjugate and uses the oligonucleotide as a tool for in situ proximity ligation. Compared with the existing in situ proximity ligation, it can produce a higher signal-to-noise ratio and signal amplification rate.

[0005] The above-mentioned methods based on existing in situ proximity ligation are mainly used to detect the proximity between proteins to obtain the number of signals of protein-protein interactions. However, it is crucial to obtain the amount of free protein that can be used to normalize the data, which helps to reduce the number of false positive signals and improve the accuracy of quantitative protein interactions. MolBoolean technology is able to detect proteins A and B that are not involved in the interaction, as well as protein AB complexes that are close enough to form. In addition, this method can accurately and relatively quantify protein interactions by calculating the number of overlapping and free rolling circle amplification products. By simultaneously detecting single proteins and protein interactions, MolBoolean technology is able to reflect the heterogeneity of single cells, which is particularly important in malignant tumors because tumor cells are mixed with stromal tissues and have different clonal characteristics.

[0006] Although existing methods for detecting protein interactions have made some progress, their efficiency still needs to be improved to meet the growing needs of biomedical research. Summary of the invention

[0007] The purpose of the present invention is to overcome the defects of the prior art and provide a method for improving the detection efficiency of in situ proximity ligation technology.

[0008] The technical solution of the present invention is as follows:

[0009] A method for improving the detection efficiency of in situ proximity ligation technology comprises the following steps:

[0010] (1) treating cells in a sample to be tested with a first primary antibody corresponding to a first protein and a second primary antibody corresponding to a second protein, wherein the cells contain the first protein and the second protein;

[0011] (2) conjugating a first secondary antibody corresponding to the first primary antibody and a second secondary antibody corresponding to the second primary antibody to the first oligonucleotide and the second oligonucleotide, respectively, to form a first conjugate and a second conjugate;

[0012] (3) treating the sample to be tested that has been treated with the first primary antibody and the second primary antibody together with the first conjugate and the second conjugate;

[0013] (4) After the treatment in step (3), a splint probe is first added to the sample to be tested to make the first oligonucleotide and the second oligonucleotide close to each other, and the splint probe is complementary to a part of the sequence of the first oligonucleotide and the second oligonucleotide respectively; then a ring-forming probe is added to obtain a circular template, and the ring-forming probe is complementary to another part of the sequence of the first oligonucleotide and the second oligonucleotide; then rolling circle amplification is performed based on the circular template to obtain a rolling circle amplification product; then a detection probe is added to identify the rolling circle amplification product, and then detection is performed by a detection device to determine the interaction between the first protein and the second protein.

[0014] In a preferred embodiment of the present invention, in step (4), a splint probe is first added for treatment, and the splint probe is complementary to a part of the sequence of the first oligonucleotide and the second oligonucleotide, respectively, so that the first oligonucleotide and the second oligonucleotide are close to each other to form a stable V-shaped structure.

[0015] In a preferred embodiment of the present invention, the detection probe is labeled with a fluorescent group.

[0016] In a preferred embodiment of the present invention, the first primary antibody and the second primary antibody are of different species origin.

[0017] Further preferably, the first secondary antibody and the second secondary antibody are of the same or different species.

[0018] More preferably, the first primary antibody and the second primary antibody are derived from rabbit and mouse, respectively.

[0019] Still more preferably, the first secondary antibody and the second secondary antibody are both derived from goats.

[0020] In a preferred embodiment of the present invention, the sample to be tested is an in vitro cultured cell sample or a tissue section sample.

[0021] Further preferably, the tissue sections are paraffin-embedded tissue sections fixed with formalin or fresh frozen sections.

[0022] Further preferably, the in vitro cultured cell sample is a cell slide.

[0023] The beneficial effects of the present invention are:

[0024] 1. The present invention introduces a splint probe that can specifically recognize and bind to two specific oligonucleotide sequences on the antibody-oligonucleotide conjugate to form a stable V-shaped structure. The V-shaped structure serves as a circularization template and can effectively mediate the circularization process of the circularization probe.

[0025] 2. Compared with the short sequence probes used in the prior art, the introduction of the splint probes of the present invention significantly improves the cyclization efficiency and detection sensitivity, and solves the problems of low hybridization efficiency and cyclization.

[0026] 3. The structure formed by the circularized probe in the present invention is different from that in the traditional method, and only has one 3' end complementary to the circular DNA molecule. This design reduces the competition between the two primer ends during the rolling circle amplification process, thereby improving the detection efficiency.

[0027] 4. The present invention realizes the quantitative and localized detection of protein interactions in cells and tissues by highly integrating proximity ligation technology, rolling circle amplification technology and in situ hybridization technology, which not only improves the sensitivity and efficiency of protein interaction detection, but also provides a new technical means for the study of protein interactions in cells and tissues. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 It is a schematic diagram of the principle of the present invention.

[0029] Figure 2 This is a diagram of the experimental results of Example 1 of the present invention.

[0030] Figure 3 This is a diagram of the experimental results of Example 2 of the present invention. DETAILED DESCRIPTION

[0031] The technical solution of the present invention is further illustrated and described below through specific embodiments combined with the accompanying drawings. Example 1 Comparative experiment of improved in situ proximity ligation and existing in situ proximity ligation on MCF-7 and HeLa cell slides

[0032] The antibodies used in this example are shown in Table 1, and the oligonucleotide and probe sequences are shown in Table 2.

[0033] Table 1

[0034]

[0035]

[0036] Table 2

[0037]

[0038] (I) Synthesis of antibody-oligonucleotide conjugates:

[0039] This example uses a 50-kDa Amicon Ultra 0.5mL centrifugal filter column to concentrate two different types of secondary antibodies, goat anti-rabbit IgG H&L and goat anti-mouse IgG H&L, respectively, and replace their buffers with phosphate buffered saline (PBS). Next, the two secondary antibodies were reacted with a 25-fold molar excess of dibenzocyclooctyne-PEG4-N-hydroxysuccinimide ester (DBCO) in dimethyl sulfoxide. The reaction mixture was incubated on ice for 2 hours. After the incubation was completed, the DBCO-conjugated antibody was purified using a 50-kDa molecular weight cutoff concentrator. Then, about 50 μg of the purified DBCO-conjugated antibody was mixed with an equal volume (dissolved in PBS) of 80 μM azide-modified oligonucleotide, and the mixture was reacted overnight at 4°C. After the reaction was completed, the obtained antibody-oligonucleotide conjugate was properly stored at 4°C for subsequent use. For goat anti-rabbit IgG H&L, the oligonucleotide coupled thereto is oligonucleotide L; for goat anti-mouse IgG H&L, the oligonucleotide coupled thereto is oligonucleotide R;

[0040] (II) Cell culture, fixation and pretreatment:

[0041] MCF-7 and HeLa cells were cultured in DMEM medium containing 10% fetal bovine serum and 1% penicillin-streptomycin solution, and the incubator was maintained at 37°C and 5% CO2. When the cells grew to 70-90% density and adhered to the slide, 0.25% (w / v) trypsin-EDTA solution was used to digest the cells, followed by centrifugation at 1000rpm for 5 minutes, and fresh culture medium was replaced. The cell suspension was evenly added dropwise to the slide, and the culture medium was discarded when the cells adhered and grew to 70-90% density. Then, the cells were washed 3 times with a mixture of 1×PBS and 0.1% diethylpyrocarbonate (DEPC), each lasting 3 minutes. Then, the cells were fixed with 4% paraformaldehyde for 15 minutes. Afterwards, the slide was washed 3 times with 1×DEPC-PBS buffer for 3 minutes each. Subsequently, the cells were placed in 70%, 95% and anhydrous ethanol for gradient dehydration, each step lasting 5 minutes. After processing, the cell slides were stored in a -80°C refrigerator for later use.

[0042] Before use, take the cell slide out of the -80°C refrigerator, dry it at room temperature, and draw a hydrophobic ring on the slide to prevent liquid diffusion. After that, wash the cell slide 3 times with 1×DEPC-Tris buffered saline (TBS), 1 minute each time. Subsequently, permeabilize the cells with 1×TBS solution containing 0.2% v / v Triton X-100 for 10 minutes, and then wash them with 1×TBS (TBST) containing 0.1% v / v Tween-20 for 2 minutes. At this point, the cell slide is ready and can be used for subsequent experiments.

[0043] (III) Figure 1 As shown, the improved in situ proximity ligation technology of this embodiment includes the following steps:

[0044] (1) Incubation of primary antibody and antibody-oligonucleotide conjugate:

[0045] A. The pre-treated cell slides were blocked and incubated at 37°C for 1 hour using a blocking buffer (Li-Cor) containing 2.5 mg / mL salmon sperm DNA.

[0046] B. Use the blocking buffer to dilute the Anti-E-cadherin rabbit antibody (primary antibody) and the Anti-β-catenin mouse antibody (primary antibody), respectively, and add the diluted mixture of the two primary antibodies onto the cell slide and incubate overnight at 4°C.

[0047] C. Place the cell slides in 1× TBST buffer and wash on a shaker three times for 3 minutes each time to remove unbound primary antibody.

[0048] D. Dilute the two antibody-oligonucleotide conjugates prepared in step (i) in a blocking buffer at an appropriate ratio, add them dropwise onto the cell slide, and incubate at room temperature for 1 hour.

[0049] E. After incubation, place the cell slides in 1× TBST buffer again and wash on a shaker three times for 5 minutes each time to remove unbound probes.

[0050] (2) Splint probe recognition hybridization (in contrast, the existing in situ proximity ligation technology does not have this step and directly proceeds to the following step (3)):

[0051] A. Place the cell slides in a humidified chamber and incubate for 1 hour in hybridization buffer containing 1×T4 DNA ligase buffer supplemented with 0.2μg / μL BSA, 0.2% Tween-20, 0.25M NaCl, 0.1mg / mL salmon sperm DNA, and 10nM splint probe. All operations were performed at 37°C.

[0052] B. After incubation, transfer the cell slides to 1× TBST buffer and wash on a shaker three times for 5 minutes each to remove unbound components.

[0053] (3) Probe closure and rolling circle amplification:

[0054] A. For the hybridization of the looped probes, looped probe 1 and looped probe 2 were added in equal moles to a hybridization buffer (the same hybridization buffer as in step (2) but without the splint probe) to a final concentration of 50 nM, and hybridized at 37°C for 1 hour.

[0055] B. After hybridization, wash the cell slides three times with 1× TBST buffer on a shaker for 1 minute each time.

[0056] C. Prepare T4 ligation solution, which contains 1× T4 DNA ligase buffer supplemented with 0.2 μg / μL BSA, 0.2% Tween-20, 0.125 M NaCl, 1 mM ATP, and 0.05 U / μL T4 DNA ligase, and incubate at 37°C for 30 minutes.

[0057] D. For rolling circle amplification reaction, place the cell slide in an amplification system containing 1×EquiPhi29 polymerase buffer, 0.2μg / μL BSA, 1mM dNTPs, 5% glycerol, 1mM DTT and 1U / μL EquiPhi29 polymerase, and react at 42°C for 90 minutes.

[0058] (4) Detection probe hybridization rolling circle amplification product:

[0059] A. For hybridization of the detection probe, a 2×SSC solution containing 20% ​​formamide, 0.1 mg / mL salmon sperm DNA, and 0.1 μM detection probe were mixed and reacted at 30° C. in a dark, humid box for 30 minutes.

[0060] B. After hybridization, wash the cell slides three times with 1× TBST buffer in a dark environment, each time for 1 minute.

[0061] C. Dry the cell slides at 37°C in the dark.

[0062] D. Use SlowFade Gold antifade reagent containing DAPI to seal the cell slides, ensuring that they are kept away from light during the sealing process.

[0063] E. Use a fluorescence microscope to image and analyze the cell crawling after sealing.

[0064] The experimental results are as follows Figure 2As shown, in this example, a specific honeycomb interaction pattern was clearly observed on the plasma membrane of MCF-7 cells, which intuitively reflects the co-localization of E-cadherin and β-catenin proteins at the adhesion junction and their interaction. In contrast, since HeLa cells express N-cadherin but not E-cadherin, no significant interaction between E-cadherin and β-catenin was detected in this cell line, and only a small amount of nonspecific positive signals was observed.

[0065] Further analysis showed that when the improved in situ proximity ligation technique was used at a concentration of 0.3 μM, its detection rate was significantly higher than the detection effect at a concentration of 0.03 μM. More significantly, even at a low concentration of 0.03 μM, the detection efficiency of the improved in situ proximity ligation was much higher than the performance of the existing in situ proximity ligation technique at a concentration of 0.3 μM. This result strongly proves that compared with the existing in situ proximity ligation technique, the improved in situ proximity ligation technique of this embodiment exhibits significantly improved detection efficiency and sensitivity in detecting protein interactions.

[0066] Example 2 Comparison of Improved In Situ Proximity Ligation and Existing In Situ Proximity Ligation on Formalin-Fixed and Paraffin-Embedded (FFPE) Human Colorectal Cancer and Human Skin Tissue Sections

[0067] The antibodies, oligonucleotides and probe sequences used in this example are the same as those in Example 1.

[0068] (I) Synthesis of antibody-oligonucleotide conjugates:

[0069] (1) Two different types of secondary antibodies, goat anti-rabbit IgG H&L and goat anti-mouse IgG H&L, were concentrated using a 50-kDa Amicon Ultra 0.5 mL centrifugal filter column, and the buffer was replaced with phosphate-buffered saline (PBS).

[0070] (2) The two secondary antibodies were reacted with 25-fold molar excess of DBCO in dimethyl sulfoxide, and the reaction mixture was incubated on ice for 2 hours.

[0071] (3) Purify the DBCO-conjugated antibody using a 50-kDa molecular weight cutoff concentrator.

[0072] (4) About 50 μg of the purified DBCO-conjugated antibody was mixed with an equal volume of 80 μM azide-modified oligonucleotide (dissolved in PBS), and the mixture was reacted at 4°C overnight.

[0073] (5) After the reaction is completed, the prepared antibody-oligonucleotide conjugate is properly stored at 4°C for subsequent use.

[0074] (II) Pretreatment of paraffin sections:

[0075] (1) FFPE tissue sections were first baked at 60°C for 30 minutes to remove excess wax.

[0076] (2) The sections were immersed in xylene twice, for 15 min and 10 min respectively, to further dewax.

[0077] (3) The tissue sections were immersed in anhydrous ethanol, 95% ethanol and 70% ethanol in sequence, each time for 2 minutes, to achieve gradient dehydration.

[0078] (4) After dehydration, immerse the sections in DEPC-H2O for 2 minutes for initial hydration.

[0079] (5) The sections were placed at 95°C for 20 min for antigen retrieval to enhance the immunoreactivity of the antigen.

[0080] (6) After the tissue sections have cooled naturally to room temperature, draw a hydrophobic ring on the sections to prevent the diffusion of liquid in subsequent steps.

[0081] (7) Wash the sections three times with 1× TBST, each wash lasting 1 min, to remove residual reagents and impurities.

[0082] (8) The slices were permeabilized with 1×TBS solution containing 0.2% v / v Triton X-100 for 20 min to increase the permeability of the cell membrane.

[0083] (9) After permeabilization, the sections were washed again with 1× TBST for 2 min in preparation for the subsequent immunostaining step.

[0084] (III) Improved in situ proximity ligation (e.g. Figure 1 shown):

[0085] (1) Incubation of primary antibody and antibody-oligonucleotide conjugate:

[0086] A. The pre-treated FFPE tissue sections were blocked and incubated at 37°C for 1 hour using a blocking buffer (Li-Cor) containing 2.5 mg / mL salmon sperm DNA.

[0087] B. Use the blocking buffer to dilute the Anti-E-cadherin rabbit antibody (primary antibody) and Anti-β-catenin mouse antibody (primary antibody), respectively, and add the diluted two primary antibody mixtures onto the FFPE tissue sections and incubate overnight at 4°C.

[0088] C. After incubation, place the FFPE tissue sections in 1× TBST buffer and wash on a shaker three times, each time for 3 minutes, to remove unbound primary antibody.

[0089] D. Dilute the two antibody-oligonucleotide conjugates prepared in step (i) in a blocking buffer at an appropriate ratio, add them dropwise to the FFPE tissue sections, and incubate at room temperature for 1 hour.

[0090] E. After incubation, place the FFPE tissue sections in 1× TBST buffer again and wash on a shaker three times for 5 minutes each to remove unbound probes.

[0091] (2) Splint primer recognition hybridization (in contrast, the existing in situ proximity ligation technology does not have this step and directly proceeds to the following step (3)):

[0092] A. Place the slides in a humidified chamber and incubate for 1 h in hybridization buffer containing 1× T4 DNA ligase buffer supplemented with 0.2 μg / μL BSA, 0.2% Tween-20, 0.25 M NaCl, 0.1 mg / mL salmon sperm DNA, and 10 nM splint probe, all at 37°C.

[0093] B. After incubation, transfer the slides to 1× TBST buffer and wash three times on a shaker for 5 minutes each to remove unbound components.

[0094] (3) Probe closure and rolling circle amplification:

[0095] A. Add the looped probe to hybridization buffer (the same hybridization buffer as in step (2) but without the splint probe) to a final concentration of 50 nM and hybridize at 37°C for 1 hour.

[0096] B. After hybridization, wash the slides three times with 1× TBST buffer on a shaker for 1 minute each time.

[0097] C. Prepare T4 ligation solution, which contains 1× T4 DNA ligase buffer supplemented with 0.2 μg / μL BSA, 0.2% Tween-20, 0.125 M NaCl, 1 mM ATP, and 0.05 U / μL T4 DNA ligase, and incubate at 37°C for 30 minutes.

[0098] D. For rolling circle amplification reaction, the cells were placed in an amplification system containing 1×EquiPhi29 polymerase buffer, 0.2 μg / μL BSA, 1 mM dNTPs, 5% glycerol, 1 mM DTT and 1 U / μL EquiPhi29 polymerase, and reacted at 42°C for 90 minutes.

[0099] (4) Fluorescence detection probe hybridization rolling circle amplification product:

[0100] A. Mix 2×SSC solution containing 20% ​​formamide, 0.1 mg / mL salmon sperm DNA, and 0.1 μM detection probe, and react at 30°C in a dark, humid box for 30 minutes.

[0101] B. After hybridization, wash the sections three times for 1 minute each time using 1× TBST buffer in a dark environment.

[0102] C. Dry the sections at 37°C in the dark.

[0103] D. Use SlowFade Gold antifade reagent containing DAPI to seal the sections, making sure to keep them away from light during the sealing process.

[0104] E. Use fluorescence microscopy to image and analyze the slices after sealing.

[0105] The experimental results are as follows Figure 3 As shown, the improved in situ proximity ligation technique showed clearly visible honeycomb-shaped strong signal points when detecting the β-catenin / E-cadherin complex on FFPE human colorectal cancer tissue. These signal points are tight and concentrated, reflecting the high level of interaction of the protein complex. In contrast, the existing in situ proximity ligation technology shows more dispersed signal points, and its signal intensity and positioning accuracy are not as good as this embodiment. In addition, when these two techniques were applied to FFPE human skin samples, it was found that the β-catenin / E-cadherin complex showed obvious strong signal points in the epidermal area, which further verified the effectiveness of these two techniques in identifying specific protein interactions. Due to the absence of E-cadherin in the dermis and its main presence in the epidermis, this finding not only proves the accuracy of the experimental results, but also highlights the robustness and specificity of the improved in situ proximity ligation technology of this embodiment in identifying tissue-specific protein interactions. Therefore, the research of this embodiment provides strong support for the application of improved in situ proximity ligation technology in biomedical research.

[0106] It should be noted that, in the above embodiments, oligonucleotide L and oligonucleotide R can be respectively connected to two primary antibodies by the same method used for coupling with the secondary antibody, and then co-incubated with the cells in the sample to be processed, and then the subsequent steps are carried out according to steps (2) to (4) of (III), and the same or similar technical effects as those of embodiments 1 and 2 can be obtained.

[0107] The above description is only a preferred embodiment of the present invention, and therefore cannot be used to limit the scope of the present invention. That is, equivalent changes and modifications made according to the patent scope of the present invention and the contents of the specification should still fall within the scope of the present invention.

Claims

1. A method for improving the detection efficiency of in situ proximity ligation technology, Features: The steps include: (1) treating cells in a sample to be tested with a first primary antibody corresponding to a first protein and a second primary antibody corresponding to a second protein, wherein the cells contain the first protein and the second protein; (2) conjugating a first secondary antibody corresponding to the first primary antibody and a second secondary antibody corresponding to the second primary antibody to the first oligonucleotide and the second oligonucleotide, respectively, to form a first conjugate and a second conjugate; (3) treating the sample to be tested that has been treated with the first primary antibody and the second primary antibody together with the first conjugate and the second conjugate; (4) After the treatment in step (3), a splint probe is first added to the sample to be tested to make the first oligonucleotide and the second oligonucleotide close to each other, and the splint probe is complementary to a part of the sequence of the first oligonucleotide and the second oligonucleotide respectively; then a ring-forming probe is added to obtain a circular template, and the ring-forming probe is complementary to another part of the sequence of the first oligonucleotide and the second oligonucleotide; then rolling circle amplification is performed based on the circular template to obtain a rolling circle amplification product; then a detection probe is added to identify the rolling circle amplification product, and then detection is performed by a detection device to determine the interaction between the first protein and the second protein.

2. The method according to claim 1, Features: In the step (4), a splint probe is first added for treatment, and the splint probe is complementary to a part of the sequence of the first oligonucleotide and the second oligonucleotide, respectively, so that the first oligonucleotide and the second oligonucleotide are close to each other to form a stable V-shaped structure.

3. The method according to claim 1, Features: The detection probe is labeled with a fluorescent group.

4. The method according to claim 1, Features: The first primary antibody and the second primary antibody are derived from different species.

5. The method according to claim 4, Features: The first secondary antibody and the second secondary antibody may be of the same or different species.

6. The method according to claim 5, Features: The first and second primary antibodies were from rabbit and mouse, respectively.

7. The method according to claim 6, Features: The first and second secondary antibodies were both from goat.

8. The method according to any one of claims 1 to 7, Features: The sample to be tested is a cell sample cultured in vitro or a tissue section sample.

9. The method according to claim 8, Features: The tissue sections are paraffin-embedded tissue sections fixed with formalin or fresh frozen sections.

10. The method according to claim 8, Features: The cell sample cultured in vitro is a cell slide.

Citation Information

Cited By

  • Ultrasensitive immunodetection method based on adjacent nucleic acid amplification signal amplification

    CN120249442A

  • An ultrasensitive immunoassay method based on proximity nucleic acid amplification signal amplification

    CN120249442B

  • Probe combination for detecting mitochondrial respiratory chain super complex based on proximity ligation assay and hybridization chain reaction and application

    CN120272591A

  • A probe combination for detecting mitochondrial respiratory chain supercomplex based on proximity ligation technology and hybridization chain reaction and its application

    CN120272591B

  • Primer probe group, proximity ligation kit and proximity ligation method for detecting interaction of circular RNA and protein and application of proximity ligation kit and proximity ligation method

    CN121450777A